Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 133 entries
View as:

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05329025 Org: User:
Start: 06/01/22 End: 01/01/24 Due: 01/01/25

A Study of QL1706 in Subjects With Advanced Malignant Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04296994 Org: User:
Start: 03/31/20 End: 12/31/23 Due: 12/31/24

Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05528198 Org: User:
Start: 12/28/18 End: 05/14/19 Due: 05/14/20

A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01931943 Org: User:
Start: 04/30/13 End: - Due: -

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Phase: N/A Priority: Normal
NCT ID: NCT05487391 Org: User:
Start: 12/08/22 End: 05/22/29 Due: 05/22/30

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04651036 Org: User:
Start: 11/06/20 End: 11/30/22 Due: 11/30/23

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06232902 Org: User:
Start: 06/20/24 End: 11/18/24 Due: 11/18/25

Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06880276 Org: User:
Start: 03/31/25 End: 05/31/27 Due: 05/31/28

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase: N/A Priority: Normal
NCT ID: NCT06671548 Org: User:
Start: 01/31/25 End: 02/28/27 Due: 02/28/28

Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

Phase: N/A Priority: Normal
NCT ID: NCT06644495 Org: User:
Start: 12/31/24 End: 04/30/27 Due: 04/30/28

Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05716126 Org: User:
Start: 04/15/20 End: 01/13/21 Due: 01/13/22

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05851027 Org: User:
Start: 01/15/21 End: 09/10/21 Due: 09/10/22

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

Phase: N/A Priority: Normal
NCT ID: NCT06633718 Org: User:
Start: 10/31/24 End: 05/30/27 Due: 05/30/28

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT07018050 Org: User:
Start: 07/31/25 End: 07/31/28 Due: 07/31/29

A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT06649214 Org: User:
Start: 11/30/24 End: 05/31/26 Due: 05/31/27

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04641754 Org: User:
Start: 03/07/19 End: 03/31/21 Due: 03/31/22

Study on the Efficacy and Safety of QLM1016 in Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT06799559 Org: User:
Start: 05/31/25 End: 12/31/26 Due: 12/31/27

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06371534 Org: User:
Start: 04/12/24 End: 04/30/25 Due: 04/30/26

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD)

Phase: N/A Priority: Normal
NCT ID: NCT05055687 Org: User:
Start: 07/05/20 End: 07/27/20 Due: 07/27/21

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06994507 Org: User:
Start: 07/31/25 End: 06/30/27 Due: 06/30/28

A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Phase: N/A Priority: Normal
NCT ID: NCT05823285 Org: User:
Start: 03/22/23 End: 06/15/27 Due: 06/15/28

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05554913 Org: User:
Start: 11/08/22 End: 02/20/24 Due: 02/20/25

Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05932888 Org: User:
Start: 06/25/23 End: 08/30/23 Due: 08/30/24

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Phase: N/A Priority: Normal
NCT ID: NCT06614907 Org: User:
Start: 08/31/24 End: 12/27/24 Due: 12/27/25

Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06864793 Org: User:
Start: 05/31/25 End: 04/30/26 Due: 04/30/27